Galapagos NV has taken further steps to consolidate its portfolio following the decision, taken with partner Gilead Sciences Inc in late 2020, not to pursue a US marketing authorisation for the rheumatoid arthritis drug Jyseleca (filgotinib). As a consequence, it is refocusing its research efforts on inflammation, fibrosis and kidney diseases. It is discontinuing research in metabolic diseases and in osteoarthritis.
